Radioiodine Dosimetry with Recombinant Human Thyrotropin

Robert Michael Tuttle; Ravinder K. Grewal; Richard J. Robbins

doi:10.1007/978-1-4939-3314-3_60

Radioiodine Dosimetry with Recombinant Human Thyrotropin

Robert Michael Tuttle, Ravinder K. Grewal, Richard J. Robbins

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Although radioactive iodine (RAI) has been an essential tool in the management of thyroid cancer for more than 60 years, there continues to be a lack of scientific rigor regarding the optimal choice of administered activity for individual patients. Often, activities of 30–75 mCi are administered for RAI remnant ablation, 100–150 mCi for adjuvant therapy in patients at significant risk of having microscopic residual disease, while activities ranging from 150 to 250 mCi are usually reserved for treatment of known metastatic disease. In most cases, the activity selected is based on an empiric regimen without knowledge of the rate of RAI clearance or specific lesional dosimetry for that individual patient.

Original language	English (US)
Title of host publication	Thyroid Cancer
Subtitle of host publication	A Comprehensive Guide to Clinical Management
Publisher	Springer Science+Business Media
Pages	657-664
Number of pages	8
ISBN (Electronic)	9781493933143
ISBN (Print)	9781493933129
DOIs	https://doi.org/10.1007/978-1-4939-3314-3_60
State	Published - Jan 1 2016

Keywords

Adjuvant therapy
Radioactive iodine (RAI)
Radioiodine dosimetry
Recombinant human thyrotropin (rhTSH)
Remnant ablation

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-1-4939-3314-3_60

Cite this

@inbook{aab0a02ff73749d994af60f398ea21dd,

title = "Radioiodine Dosimetry with Recombinant Human Thyrotropin",

abstract = "Although radioactive iodine (RAI) has been an essential tool in the management of thyroid cancer for more than 60 years, there continues to be a lack of scientific rigor regarding the optimal choice of administered activity for individual patients. Often, activities of 30–75 mCi are administered for RAI remnant ablation, 100–150 mCi for adjuvant therapy in patients at significant risk of having microscopic residual disease, while activities ranging from 150 to 250 mCi are usually reserved for treatment of known metastatic disease. In most cases, the activity selected is based on an empiric regimen without knowledge of the rate of RAI clearance or specific lesional dosimetry for that individual patient.",

keywords = "Adjuvant therapy, Radioactive iodine (RAI), Radioiodine dosimetry, Recombinant human thyrotropin (rhTSH), Remnant ablation",

author = "Tuttle, \{Robert Michael\} and Grewal, \{Ravinder K.\} and Robbins, \{Richard J.\}",

note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media New York 2016",

year = "2016",

month = jan,

day = "1",

doi = "10.1007/978-1-4939-3314-3\_60",

language = "English (US)",

isbn = "9781493933129",

pages = "657--664",

booktitle = "Thyroid Cancer",

publisher = "Springer Science+Business Media",

}

TY - CHAP

T1 - Radioiodine Dosimetry with Recombinant Human Thyrotropin

AU - Tuttle, Robert Michael

AU - Grewal, Ravinder K.

AU - Robbins, Richard J.

N1 - Publisher Copyright: © Springer Science+Business Media New York 2016

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Although radioactive iodine (RAI) has been an essential tool in the management of thyroid cancer for more than 60 years, there continues to be a lack of scientific rigor regarding the optimal choice of administered activity for individual patients. Often, activities of 30–75 mCi are administered for RAI remnant ablation, 100–150 mCi for adjuvant therapy in patients at significant risk of having microscopic residual disease, while activities ranging from 150 to 250 mCi are usually reserved for treatment of known metastatic disease. In most cases, the activity selected is based on an empiric regimen without knowledge of the rate of RAI clearance or specific lesional dosimetry for that individual patient.

AB - Although radioactive iodine (RAI) has been an essential tool in the management of thyroid cancer for more than 60 years, there continues to be a lack of scientific rigor regarding the optimal choice of administered activity for individual patients. Often, activities of 30–75 mCi are administered for RAI remnant ablation, 100–150 mCi for adjuvant therapy in patients at significant risk of having microscopic residual disease, while activities ranging from 150 to 250 mCi are usually reserved for treatment of known metastatic disease. In most cases, the activity selected is based on an empiric regimen without knowledge of the rate of RAI clearance or specific lesional dosimetry for that individual patient.

KW - Adjuvant therapy

KW - Radioactive iodine (RAI)

KW - Radioiodine dosimetry

KW - Recombinant human thyrotropin (rhTSH)

KW - Remnant ablation

UR - https://www.scopus.com/pages/publications/105013223332

UR - https://www.scopus.com/inward/citedby.url?scp=105013223332&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-3314-3_60

DO - 10.1007/978-1-4939-3314-3_60

M3 - Chapter

AN - SCOPUS:105013223332

SN - 9781493933129

SP - 657

EP - 664

BT - Thyroid Cancer

PB - Springer Science+Business Media

ER -

Radioiodine Dosimetry with Recombinant Human Thyrotropin

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this